低剂量甲氨蝶呤与老年慢性肾脏病患者严重不良事件
这项在加拿大安大略省开展的回顾性、基于人群的新用药者队列研究(2008-2021年)纳入66岁及以上、eGFR<60 mL/min/1.73 m2且未透析的CKD患者,将起始低剂量甲氨蝶呤(5-35 mg/wk)者与起始羟氯喹(200-400 mg/d)者按1:1倾向评分匹配,各2309例。主要终点为起始用药后90天内因骨髓抑制、脓毒症、肺毒性或肝毒性就诊住院的复合终点,甲氨蝶呤组82/2309(3.55%)高于羟氯喹组40/2309(1.73%),RR 2.05(95%CI 1.42-2.96),RD 1.82%(95%CI 0.91%-2.73%)。亚组分析显示eGFR越低风险越高,如eGFR<45 mL/min/1.73 m2时RR 2.79(95%CI 1.51-5.13)。作者认为若这些风险得到验证,应与低剂量甲氨蝶呤的获益进行权衡。
要点
- 老年CKD患者起始低剂量甲氨蝶呤后90天严重不良事件复合终点为3.55%(82/2309),高于羟氯喹的1.73%(40/2309),RR 2.05(95%CI 1.42-2.96)。
- 绝对风险差为1.82%(95%CI 0.91%-2.73%),即每治疗约55例此类患者90天内可能多1例严重不良事件。
- 风险随eGFR下降而升高,eGFR<45 mL/min/1.73 m2者RR 2.79(95%CI 1.51-5.13)。
- 与羟氯喹相比,甲氨蝶呤15-35 mg/wk剂量组主要终点风险更高。
- 主要终点为90天内因骨髓抑制、脓毒症、肺毒性或肝毒性就诊住院的复合终点。
适用人群与场景
- 加拿大安大略省66岁及以上、eGFR<60 mL/min/1.73 m2且未接受透析的CKD成人,起始低剂量甲氨蝶呤(5-35 mg/wk)或羟氯喹(200-400 mg/d)者。
- 研究基于2008-2021年关联行政健康数据,为回顾性、基于人群的新用药者队列。
诊断标准与关键阈值
- CKD定义为eGFR<60 mL/min/1.73 m2且未接受透析。
- 主要终点为起始研究药物后90天内因骨髓抑制、脓毒症、肺毒性或肝毒性就诊住院的复合终点。
研究设计与关键结果
- 回顾性、基于人群的新用药者队列研究,倾向评分匹配1:1后纳入4618例(甲氨蝶呤组2309例,羟氯喹组2309例),3192例(69%)为女性,中位年龄76岁(IQR 71-82)。
- 主要终点:甲氨蝶呤组82/2309(3.55%)vs 羟氯喹组40/2309(1.73%),RR 2.05(95%CI 1.42-2.96),RD 1.82%(95%CI 0.91%-2.73%)。
- 亚组分析显示eGFR越低风险越高,如eGFR<45 mL/min/1.73 m2时RR 2.79(95%CI 1.51-5.13)。
- 与羟氯喹的次要比较中,甲氨蝶呤15-35 mg/wk使用者主要终点风险更高。
证据类型、等级与局限
- 证据类型:回顾性、基于人群的新用药者队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,若这些风险得到验证,应与低剂量甲氨蝶呤的获益进行权衡。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Low-dose methotrexate is used to treat rheumatoid arthritis and psoriasis. Due to its kidney elimination, better evidence is needed to inform its safety in adults with chronic kidney disease (CKD).
OBJECTIVES: To compare the 90-day risk of serious adverse events among adults with CKD who started low-dose methotrexate vs those who started hydroxychloroquine and to compare the risk of serious adverse events among adults with CKD starting 2 distinct doses of methotrexate vs those starting hydroxychloroquine.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based, new-user cohort study was conducted in Ontario, Canada (2008-2021) using linked administrative health care data. Adults aged 66 years or older with CKD (defined as an estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 but not receiving dialysis) who started low-dose methotrexate (n = 2309) were matched 1:1 with those who started hydroxychloroquine.
EXPOSURE: Low-dose methotrexate (5-35 mg/wk) vs hydroxychloroquine (200-400 mg/d).
MAIN OUTCOME AND MEASURE: The primary outcome was a composite of serious adverse events: a hospital visit with myelosuppression, sepsis, pneumotoxic effects, or hepatotoxic effects within 90 days of starting the study drug. Prespecified subgroup analyses were conducted by eGFR category. Propensity score matching was used to balance comparison groups on indicators of baseline health. Risk ratios (RRs) were obtained using modified Poisson regression, and risk differences (RDs) using binomial regression.
RESULTS: In a propensity score-matched cohort of 4618 adults with CKD (3192 [69%] women; median [IQR] age, 76 [71-82] years), the primary outcome was higher in patients who started low-dose methotrexate vs those who started hydroxychloroquine (82 of 2309 [3.55%] vs 40 of 2309 [1.73%]; RR, 2.05 (95% CI, 1.42-2.96); RD, 1.82% [95% CI, 0.91%-2.73%]). In subgroup analysis, the risks increased progressively at lower eGFR (eg, eGFR <45 mL/min/1.73 m2: RR, 2.79 [95% CI, 1.51-5.13]). In the secondary comparison with hydroxychloroquine, methotrexate users at 15 to 35 mg/wk had a higher risk of the primary outcome.
CONCLUSIONS AND RELEVANCE: In this cohort of 4618 older patients with CKD, the 90-day risk of serious adverse events was higher among those who started low-dose methotrexate than those who started hydroxychloroquine. If verified, these risks should be balanced against the benefits of low-dose methotrexate use.
参考来源
- Muanda FT, Blake PG, Weir MA, et al. Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease. JAMA Netw Open. 2023. PMID: 38010652. doi:10.1001/jamanetworkopen.2023.45132
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。